13 April 2026
13 April 2026
The partnership reflects a focus on precision oncology, seeking to enhance patient selection and assess treatment responses.
This deal falls into the wider pipeline restocking trend in pharma, as companies look to protect their revenue amid looming patent expirations.
This partnership meshes with OBT’s hybrid partnership-pipeline strategy, which prioritises collaboration to extend its market impact.
Replimune’s RP1 is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response.
Standard of care HNSCC regimens with curative intent demand surgery, radiation, and chemotherapy - treatments that many patients cannot tolerate.
C4 Therapeutics will receive $20m upfront in addition to milestone payments, with a potential $1bn in additional milestones.
Kelly Parliament, staff application scientist at Beckman Coulter Life Sciences, discusses how automation is improving the efficiency of single-cell transcriptomic workflows.
The rare disease framework has had a turbulent past few years, with the FDA looking to create regulatory stability.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
